Vaccine-Induced Boosting of Influenza Virus-Specific CD4 T Cells in Younger and Aged Humans
Open accessAbstract
Current yearly influenza virus vaccines induce strain-specific neutralizing antibody (NAb) responses providing protective immunity to closely matched viruses. However, these vaccines are often poorly effective in high-risk groups such as the elderly and challenges exist in predicting yearly or emerging pandemic influenza virus strains to include in the vaccines. Thus, there has been considerable emphasis on understanding broadly protective immunological mechanisms for influenza virus. Recent studies have implicated memory CD4 T cells in heterotypic immunity in animal models and in human challenge studies. Here we examined how influenza virus vaccination boosted CD4 T cell responses in younger versus aged humans. Our results demonstrate that while the magnitude of the vaccine-induced CD4 T cell response and number of subjects responding on day 7 did not differ between younger and aged subjects, fewer aged subjects had peak responses on day 14. While CD4 T cell responses were inefficiently boosted against NA, both HA and especially nucleocaspid protein- and matrix-(NP+M) specific responses were robustly boosted. Pre-existing CD4 T cell responses were associated with more robust responses to influenza virus NP+M, but not H1 or H3. Finally pre-existing strain-specific NAb decreased the boosting of CD4 T cell responses. Thus, accumulation of pre-existing influenza virus-specific immunity in the form of NAb and cross-reactive T cells to conserved virus proteins (e.g. NP and M) over a lifetime of exposure to infection and vaccination may influence vaccine-induced CD4 T cell responses in the aged.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Timepoints were chosen a priori to capture the peak antigen-specific response for primary and secondary responses in SARS-CoV-2 naïve individuals.
“Timepoints were chosen a priori to capture the peak antigen-specific response for primary (41) and secondary responses (42, 43) in SARS-CoV-2 naïve individuals.”
From Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination (2021) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 43 · Cited by 26
- Authors
- Dolfi, D. V., Mansfield, K. D., Kurupati, R. K., Kannan, S., Doyle, S. A., Ertl, H. C. J., Schmader, K. E., & Wherry, E. J.
- Affiliations
- University of Pennsylvania (US)
- The Wistar Institute (US)
- Duke Medical Center (US)
- Corresponding author
- Wherry, E. John
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-14
- Volume
- 8
- Issue
- 10
- Pages
- e77164
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3796569
- OpenAlex
- W2126816086
- Cited by
- 26
- References
- 43
- Citations by year
- 2023: 1 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 1
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Public Health Service (A1078897)
- National Institute on Aging (AG028716, P30AG028716)
- National Institute of Allergy and Infectious Diseases (AI 082630, U19AI083022, AI 083022, U19AI082630)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- influenza vaccination, CD4+ T cells, memory T cell responses, aging, heterologous immunity, pre-existing immunity, neutralizing antibodies, nucleocapsid protein, matrix protein, hemagglutinin, neuraminidase, cross-reactive T cells, booster vaccination, older adults
- MeSH terms
- Adult, Aged, Aging, Cell Differentiation, Demography, Female, Humans, Influenza Vaccines, Kinetics, Male, Orthomyxoviridae, Species Specificity, Viral Proteins, Vaccines, Inactivated, CD4-Positive T-Lymphocytes, Cell Proliferation, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review